Regeneron Announces November 2012 Investor Conference Presentations
TARRYTOWN, N.Y., Nov. 6, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:
- Lazard Capital Markets 9th Annual Healthcare Conference at 11:00 a.m. Eastern Time on Tuesday, November 13, 2012
- Credit Suisse Healthcare Conference at 9:30 a.m. Eastern Time (7:30 a.m. Mountain Time) on Wednesday, November 14, 2012
- Piper Jaffray 24th Annual Healthcare Conference at 12:00 p.m. on Wednesday, November 28, 2012
The sessions may be accessed through the Company's web site, www.regeneron.com, on the Events and Presentations page. Archived versions of the presentations will be available for thirty days after the live webcasts.
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with Sanofi. Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727. Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.
SOURCE Regeneron Pharmaceuticals, Inc.
More by this Source
Robert A. Ingram Elected to Regeneron Board of Directors
Apr 04, 2014, 16:00 ET
Regeneron Announces Initiative for STEM Education in Hudson Valley
Apr 03, 2014, 16:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.